drugset / Trial / NCT00910091

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

NCT00910091

Phase 2 Completed 73 enrolled Ipsen
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.

Timeline

Start
2009-08
Primary completion
2012-01
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Irosustat Small molecule 40 mg Oral
Comparator Megestrol Acetate Other / unclassified 160 mg Oral

Indications